Rank 60 • Biotech & Discovery
Genesis Therapeutics
Leverages deep learning and molecular simulations to discover small-molecule drugs for challenging targets.
Visit website- Signal Score
- 85.3
- Total raised
- $280M
- Stage
- Series B
- Founded
- 2019
- Headquarters
- Burlingame, USA
- Region
- North America
Their signal
Genesis applies 3D spatial AI to tackle historically undruggable protein targets. Backed by top-tier venture capitalists and major pharma deals with Lilly and Genentech, its technical execution is highly regarded.
Signal Score 85.3editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Did we miss something?
Change, add or remove details on this company. Our desk reviews every request.
Figures are subjective research desk estimates compiled from public sources and refreshed monthly, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.